Hikal, jointly promoted by Hiremath and  Kalyani group, is amongst the first companies to offer customized, cost effective and sustainable solutions from R&D to Commercial Manufacturing. It is one of the very few global and only Indian company to provide APIs for both Pharmaceuticals and Agrochemicals.  About 70% of company’s earning comes from exports and having strong marketing tie-ups with multinationals includes Bayer, Syngenta, Degussa and Pfizer. The company has two verticals – pharmaceuticals and crop protection wherein 61% of the net revenue comes from the former.

Net sales for Q4FY16 was up 36% (YoY) at Rs.290 crore and net profit came in at Rs.22 crore, up 120%.  Its raw material costs grew 37% and overall costs rose 32%. Operating profit was up 55% at Rs.42 crore.

Its pharma segment revenue grew 6% at Rs.138 crore and its EBIT slumped 6%. Crop Protection products segment showed a much better performance – sales rose 6% and EBIT was up 10%. Its interest outgo stands at Rs.12 crore and debt as at Rs.470 crore.

The company ended FY16 with a consolidated net revenue at Rs.926 crore, up 6% and net profit growth was flat at Rs.41 crore v/s Rs.40 crore in FY15. Its equity is at Rs.16.44 crore and EPS at Rs.5 (FV of Rs.2/share).

C